Latest News

Filters close
Released: 15-Dec-2017 8:30 AM EST
Results of Clinical Testing in Retinitis Pigmentosa
 jCyte

In a phase 1/2a study jCyte's investigational therapy, jCell, showed a good safety profile and indications of potential benefit for patients with retinitis pigmentosa

Comment
Released: 2-May-2017 8:00 AM EDT
jCyte Receives Regenerative Medicine Advanced Therapy Designation
 jCyte

Cell therapy company jCyte has received Regenerative Medicine Advanced Therapy designation from the FDA for their developmental retinitis pigmentosa therapy.

Comment
Released: 19-Apr-2017 7:00 AM EDT
Powered by CIRM Grant, jCyte Launches New Clinical Trial
 jCyte

Cell-based therapy company jCyte is launching a Phase 2b clinical trial to study the effectiveness of its developmental therapy for retinitis pigmentosa.

Comment
Released: 28-Nov-2016 10:00 AM EST
jCyte Completes Enrollment for Phase I/IIa Safety Trial
 jCyte

Regenerative medicine company jCyte has completed enrollment in a phase I/IIa trial studying the safety of its stem cell therapy for retinitis pigmentosa. Early results are promising.

Comment
Released: 14-Jul-2016 5:05 PM EDT
Early Trial Results Support the Safety of Cell-Based Retinitis Pigmentosa Treatment
 jCyte

Regenerative medicine company jCyte and the Sue & Bill Gross Stem Cell Research Center at the University of California, Irvine report that their investigational therapy for retinitis pigmentosa (RP) has demonstrated a favorable safety and tolerability profile in an ongoing Phase I/II clinical trial.

Comment


close
0.08569